1. Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification

   • Guoliang Yao
   • Jianyong Yuan
   • Jingbo Chen

   Review 16 November 2023 Pages: 1 - 13

   

2. Endosomal recycling inhibitors downregulate the androgen receptor and synergise with enzalutamide

   • Kelsey A. Fletcher
   • Mai H. Alkurashi
   • Andrew J. Lindsay

   Research 14 November 2023 Pages: 14 - 23

   

3. Molecular profiling and prognostic analysis in Chinese cholangiocarcinoma: an observational, retrospective single-center study

   • Changkun Zhang
   • Xia You
   • Dong Wang

   Research 17 November 2023 Pages: 24 - 34

   

4. Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma

   • Jasmine C. Huynh
   • May Cho
   • Edward J. Kim

   Research Open access 01 December 2023 Pages: 35 - 43

   

5. A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I-

   • Daiki Tsuji
   • Shigeru Nakagaki
   • Masaya Watanabe

   Research 06 December 2023 Pages: 44 - 52

   

6. Clinical characteristics, diagnosis, treatment, and prognosis of nivolumab induced gastritis

   • Haibo Lei
   • Wei Sun
   • Chunjiang Wang

   Research 08 December 2023 Pages: 53 - 59

7. RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma

   • Yanfang Jiang
   • Xintong Hu
   • Pingwei Zhao

   Research 10 December 2023 Pages: 60 - 69

   

8. Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage

   • Yue Wang
   • Xingyu Lin
   • Guan Wang

   Research 12 December 2023 Pages: 70 - 79

   

9. Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects

   • Hyun Chul Kim
   • Eunsol Yang
   • Kyung-Sang Yu

   Research Open access 15 December 2023 Pages: 80 - 88

   

10. Targeted delivery of liposomal Ribociclib to SLC7A5 transporters in breast cancer cells

    • Mahtab Afsharzadeh
    • Jaleh Varshosaz
    • Farshid Hasanzadeh

    Research 21 December 2023 Pages: 89 - 105

    

11. A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function

    • Jingying Yue
    • Shuai Shao
    • Marie M Zhu

    Research 10 January 2024 Pages: 106 - 115

    

12. Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis

    • Meng-Ting Li
    • Yang He
    • Ji-Sheng Chen

    Research 23 January 2024 Pages: 116 - 126

    

13. Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort

    • Oluwadunni E. Emiloju
    • Jun Yin
    • Brian A. Costello

    Research 25 January 2024 Pages: 127 - 135

    

14. Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer

    • Naoyuki Nogami
    • Takaaki Tokito
    • Makoto Nishio

    Research Open access 01 February 2024 Pages: 136 - 144

    

15. CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial

    • Andrew J. Armstrong
    • Ravit Geva
    • Judy S. Wang

    Research Open access 07 February 2024 Pages: 145 - 159